Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus HYDROSERPINE PLUS R H H.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus HYDROSERPINE PLUS R H H.
ALDORIL 15 vs HYDROSERPINE PLUS (R-H-H)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination